154 related articles for article (PubMed ID: 8617477)
21. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase II alpha as a reliable proliferation marker in meningiomas.
Roessler K; Gatterbauer B; Kitz K
Neurol Res; 2002 Apr; 24(3):241-3. PubMed ID: 11958416
[TBL] [Abstract][Full Text] [Related]
23. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.
Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E
Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138
[TBL] [Abstract][Full Text] [Related]
24. Proliferation markers in gliomas: a comparison of BUDR, KI-67, and MIB-1.
Davis RL; Onda K; Shubuya M; Lamborn K; Hoshino T
J Neurooncol; 1995; 24(1):9-12. PubMed ID: 8523082
[No Abstract] [Full Text] [Related]
25. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
Vankalakunti M; Vasishta RK; Das Radotra B; Khosla VK
Neuropathology; 2007 Oct; 27(5):407-12. PubMed ID: 18018472
[TBL] [Abstract][Full Text] [Related]
26. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
27. Correlation Between Digital and Manual Determinations of Ki-67/MIB-1 Proliferative Indices in Human Meningiomas.
Pham DT; Skaland I; Winther TL; Salvesen Ø; Torp SH
Int J Surg Pathol; 2020 May; 28(3):273-279. PubMed ID: 31771372
[No Abstract] [Full Text] [Related]
28. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154
[TBL] [Abstract][Full Text] [Related]
29. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas.
Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P
Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285
[TBL] [Abstract][Full Text] [Related]
30. Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression.
Nakabayashi H; Sakaguchi M; Katsuyama J; Hakuba A
J Neurooncol; 1995; 24(3):209-17. PubMed ID: 7595751
[TBL] [Abstract][Full Text] [Related]
31. Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human tumours.
Wilson GD; Saunders MI; Dische S; Daley FM; Robinson BM; Martindale CA; Joiner B; Richman PI
Cell Prolif; 1996 Mar; 29(3):141-52. PubMed ID: 8652743
[TBL] [Abstract][Full Text] [Related]
32. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
[TBL] [Abstract][Full Text] [Related]
33. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
34. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
35. Meningioma: proliferating potential and clinicoradiological features.
Nakasu S; Nakajima M; Matsumura K; Nakasu Y; Handa J
Neurosurgery; 1995 Dec; 37(6):1049-55. PubMed ID: 8584144
[TBL] [Abstract][Full Text] [Related]
36. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
38. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas.
Antinheimo J; Haapasalo H; Haltia M; Tatagiba M; Thomas S; Brandis A; Sainio M; Carpen O; Samii M; Jääskeläinen J
J Neurosurg; 1997 Oct; 87(4):610-4. PubMed ID: 9322850
[TBL] [Abstract][Full Text] [Related]
39. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.
Cho KG; Hoshino T; Nagashima T; Murovic JA; Wilson CB
J Neurosurg; 1986 Dec; 65(6):790-4. PubMed ID: 3772477
[TBL] [Abstract][Full Text] [Related]
40. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
